Skip to main content

Mindlift (Aus Vitality Wellness Co)

Product Name
Mindlift
ARTG
370898
Date of review outcome
Date of publication
Mar-2024
Outcome
Medicine is no longer permitted to be supplied
Is it safe to continue using this medicine?
Yes, based on the sponsor's certification. However, use of this medicine may pose a safety risk for some people. Follow the recommended actions below.
What action should consumers take?
Seek advice from a medical practitioner if you have been taking this medicine to treat anxiety, depression or kidney disease, or to assist with superior semi-circular canal dehiscence, dizziness and vertigo, attention-deficit/hyperactivity disorder (ADHD), diabetes, chronic stress or chronic fatigue syndrome.
Consider whether this medicine is right for you based on it potentially not working as expected in relation to the conditions described above, as well as supporting cognitive function, neurotransmitter synthesis and memory; improving focus, visual information processing, concentration, memory, brain performance, mental clarity, energy levels, energy production, exercise endurance, VO2 max, sleep, mood and male fertility; reducing stress, insomnia and 'brain fog'; balancing or reducing cortisol levels; enhancing or modulating neurotransmitter levels; antioxidant neuroprotection; increasing cerebral blood flow; regulating stress hormones; treating low libido and exhaustion; preventing neurological symptoms as a result of magnesium depletion; improving blood health; and migraines.
Always read the label and follow the directions for use.
Review scope
Targeted
Information reviewed
ARTG Record, Website
Issues related to safety
The website for this medicine contained claims specified in 'What action should consumers take?' above. Some of these claims are not permitted for listed medicines without prior evaluation or approval from the TGA. References to non-permitted claims have the potential to lead consumers to delay access to timely advice or treatment from a suitably qualified health professional when required, which may result in adverse outcomes.
In addition, the website did not display the mandatory warning statement 'Always read the label and follow the directions for use'.
While advertising of this nature and the absence of a warning statement is unacceptable, the claims have been removed from the website and the warning statement has been added. In addition, the website for this medicine advised consumers to talk to their healthcare professional if symptoms persist. As such, this medicine is unlikely to pose an immediate risk to consumer health and safety.
Issues related to efficacy
The website for this medicine contained claims specified in 'What action should consumers take?' above. In addition, the website claimed this medicine could be used in children aged 12 to 17 years, and implied that this medicine was supported by traditional evidence. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
Actions taken during the review
The TGA required the sponsor to correct the issues with this medicine. The sponsor cancelled this medicine, withdrew it from further supply and updated their website to correct the issues.

Help us improve the Therapeutic Goods Administration site